36,266 AbbVie Inc. $ABBV Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. increased its stake in AbbVie Inc. (NYSE:ABBV) by 9.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 402,565 shares of the company’s stock after purchasing an additional 36,266 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in AbbVie were worth $104,734,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ABBV. State Street Corp raised its position in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of AbbVie by 0.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of AbbVie in the second quarter worth $2,905,952,000. Deutsche Bank AG boosted its holdings in shares of AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the period. Finally, Amundi boosted its holdings in shares of AbbVie by 2.4% during the 1st quarter. Amundi now owns 10,698,095 shares of the company’s stock worth $2,326,728,000 after buying an additional 247,689 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.7%

ABBV opened at $285.32 on Friday. The firm has a market capitalization of $504.10 billion, a P/E ratio of 80.60, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. The stock’s 50 day moving average price is $262.74 and its two-hundred day moving average price is $239.22. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the business posted $2.97 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Analyst Ratings Changes

ABBV has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Citigroup lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Argus boosted their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Wells Fargo & Company upped their price target on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Finally, Bank of America restated a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $277.18.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.